Once in a Blue Moon Academia (OBMA)

  Sloan’s “Promise”: Heritage Brand or Hazard in a Bottle? Posted on 1st October, 2025 (GMT 18:38 hrs) ABSTRACT This representation critically examines Sloan’s Liniment/Balm (Piramal Pharma), exposing concerns about its irrational Fixed Dose Combination of counter-irritants (methyl salicylate, menthol, camphor, turpentine oil, eucalyptus oil, capsaicin), absent from global pharmacopeias (USP, Ph. Eur., WHO EML) and unsupported by clinical evidence in arthritis. Risks such as systemic salicylate poisoning, camphor neurotoxicity, turpentine irritation, and capsicum hypersensitivity are compounded by misleading claims of “lasting arthritis relief,” which distract from proper treatment and may delay evidence-based care. Regulatory loopholes in India (Drugs & Cosmetics Act, 1940; Drugs and Magic Remedies Act, 1954) enable this obsolete heritage brand to persist despite international withdrawal. Sloan’s thus embodies an ethical paradox: irritants sold as therapy, financial wound...

Piramal, Polycrol, Pesticides, and the Politics of Stomachs Posted on 30th September, 2025 (GMT 11:40 hrs) ABSTRACT This letter critically examines Polycrol, an over-the-counter antacid by Piramal Pharma, as both a medical product and a metaphor for systemic socio-economic and political injustices in India. While marketed for short-term relief of digestive discomfort, Polycrol contains aluminium compounds whose chronic ingestion poses documented neurotoxic, skeletal, renal, and haematological risks, yet long-term clinical evidence of efficacy is absent. The correspondence situates the product within broader “pharma-political” dynamics, linking corporate profiteering, regulatory laxity, celebrity endorsements, and pesticide exposure to a cultural normalization of self-medication. Drawing parallels between the symptomatic relief of Polycrol and the quick-fix, extractive logic of crony capitalism—as exemplified in the DHFL financial scandal—the letter calls for regulatory transparency...